What's Happening?
Sibanye-Stillwater, a mining and metals company, has announced a collaboration with the Nuclear Energy Corporation of South Africa (Necsa) to advance nuclear medicine for cancer treatment. The partnership aims to develop a radioactive palladium isotope
derived from rhodium for use in targeted radionuclide therapy. This isotope, palladium-103, is currently used in Brachytherapy to treat localized tumors, including prostate cancer, by delivering radiation directly to the affected area, thereby limiting exposure to surrounding healthy tissue. The collaboration will involve testing and verifying the rhodium's suitability for radionuclide production and further chemical work to produce high-purity palladium-103. The project also aims to explore other nuclear medicine applications using rhodium and other platinum group metals produced by Sibanye-Stillwater.
Why It's Important?
This collaboration is significant as it represents a strategic effort to enhance cancer treatment options through advanced nuclear medicine. By developing new applications for platinum group metals, Sibanye-Stillwater and Necsa are contributing to the next generation of precision cancer therapies. This initiative not only strengthens South Africa's capability in radiopharmaceutical innovation but also positions the country as a globally respected center of excellence in nuclear research. The partnership aligns with Sibanye-Stillwater's philosophy to invest in research and development opportunities, potentially leading to breakthroughs in healthcare and expanding the use of its metals in medical applications.
What's Next?
The collaboration will proceed with the first phase focusing on testing and verifying the rhodium for radionuclide production standards. Following this, further chemical work will be conducted to produce high-purity palladium-103. The second phase will explore additional nuclear medicine applications using rhodium and other platinum group metals. This ongoing research and development effort may lead to new cancer treatment options and further strengthen South Africa's role in nuclear medicine innovation.
